Abstract
BackgroundApproximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and developed...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have